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The lesions of acne have often been found to harbor the Corynebacterium aenes, and
anaerobic diphtheroid, in the unruptured pustules. It has never been proved, however,
that this organism is etiologically related to the disease. Erythromycin has been particu-
larly active against members of the genus Corynebacteria. It was felt that if the coryne-
bacterium does contribute to the pathogenesis of acne vulgaris, then erythromycin might
be of definite benefit. With this in mind, a group of 60 patients with acne and acneiform types
of eruptions were placed on erythromycin (Ilotycin, Lilly) for periods ranging from two
weeks to three months in a dosage of 200 milligrams two or three times daily separated in
hours so as to be given every six or every eight hours. The results of this investigation are
herewith presented.
The new antibiotic erythromycin (Ilotycin) is derived from the Streptomyces erythreus
and has been described by McGuire and co-workers (1). Preliminary studies of this new
antibiotic agent made in the laboratories of Dr. Fordyce R. Heilman and his co-workers in
the Section of Bacteriology of the Mayo Clinic (2) seemed to indicate that it might be quite
active against corynebacteria. One ease of staphyloccocus infection resistant to other
antibiotics and characterized by acneiform lesions was treated and is reported in this
paper.
Ilotycin is a white, crystalline compound with an empiric formula thought to approxi-
mate C39H73NO13. The nitrogen present is not contained in a nitro group, and there is no
benzene ring structure in the formula. Its toxicity is low. The oral LD5O in mice is from
3000 to 4000 mg./kg. and the subcutaneous LD5O is greater than 2500 mg./kg. Clinical tests
have shown that Ilotycin is unusually active against most of the pyogenic infections. In the
laboratory its effectiveness against pathogenic protozoa, the larger viruses, and certain
rickettsiae has been convincingly demonstrated and is under clinical study. The most
significant aspect of this discovery is the effectiveness of the compound against some of the
common organisms which are resistant to penicillin and other antibiotics in common use.
Furthermore, it does not produce drastic changes in intestinal flora and, consequently does
not give rise to the undesirable gastrointestinal side effects so commonly associated with
administration of other broad spectrum antibiotics.
DOSAGE AND METHOD OF ADMINISTRATION
Patients were selected who had either uncomplicated acne with comedones and excessive
oiliness of the skin or who had a rather marked pyogenic phase. Some of the patients had
already had a great deal of previous therapy of all kinds. In addition to the Ilotycin therapy
they were placed on a diet low in heavy fats and greases, were given a mild astringent to
use on the skin and were asked to use a mild soap frequently. All the patients were checked
for bacterial sensitivity with staphylococcus ambotoxoid. The blood pressure, basal tem-
peratures and urinalysis were noted on all the patients. On many of the patients blood
counts were done at intervals, but there were no significant changes nor were there sig-
nificant rises in the white count in any of the cases. The Ilotycin was given at first in 200
milligram capsules, the standard dosage being 200 mgms at 7 A.M., 4 P.M. and 11 P.M. This
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flotycin (erythromycin) for this study was furnished by Dr. J. W. Smith of the Eli
Lilly Co. Indianapolis 6, Indiana.
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TABLE I
Concurrent
therapy
Duration therapy
9 female, 3 male
Local astringents,
diet
Sulphur-resorcin lo-
tion and dietary
regime
12 days one case, 21
days 10 cases, 30
days one case
12 yrs to 27 yrs
35
20 female, 15 male
In five cases none,
others local care
and dietary con-
trol
14 days six cases. 21
days twenty eases.3 months five
cases. 4 months 1
case
None
9 female, 4 male
X-ray limit in 8 cases,
astringents, diet,
vaccines in four
cases
21 days ten cases. 3
months three cases
1 case of severe diar-
rhea had to stop
treatment
Dosage schedule
Control oil and
comedones
Control pustules
Recurrence pustu-
les after stopping
Ilotycin but con-
tinuing local Rx
and diet
200 mgms capsule
morning and night
10 cases, 200 mgs
tid three cases
None visible
Excellent during
therapy (where
few lesions were
present)
No change
200 mgms tid 20
cases. 200 mgms
bid 15 cases
None visible
35% control five
cases. 60 to 75%
control in 25 cases.
Complete control
in 5 cases
5 cases remained
clear. 30 cases,
pustules recurred
avg 4 to 6 wks
200 mgms tid all cases
None visible
Moderate control in
three cases. 75% to
80% control three
cases. Complete
control 7 cases
One case remained
clear. Test relapsed
in about four weeks
time
Cooperation All patients were closely supervised and took treatment as scheduled
OBSERVATION M.D ACNE(ou. AND COMEDONES) M PUSTIILAR ACNE SEVERE PUSTULAR ACNE
13 yrs to 20 yrs
12
Age range
Number of cases
Sex
Previous therapy
15 yrs to 35 yrs
13
Same Same
Reactions None
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was continued without interruption during the period of study. In some cases the dosage was
increased to 4 capsules a day and when the enteric coated Jiotycin tablets were brought out
these were given four times a day. Photographs in color of the patients before and after
were taken in most instances and the criteria of response to the drug were the disappearance
or persistence of pustules and the recurrence of pustules after the discontinuance of therapy
for a period of some weeks. The patients were carefully questioned throughout the period
of treatment as to the development of gastro-intestinal dysfunction or the development of
pruritus or other evidences of monilial overgrowth. The age of patients range from 10 to 35
and both sexes were well represented, all of the patients coming from the Carolina coastal
country. The study was begun September 24, 1952 and completed March 1, 1953.
SUMMARY
Trial of erythromycin in sixty cases of acne vulgaris of various types resulted in ex-
cellent control of the pustular element in nearly all cases. This improvement was tem-
porary in nature with recurrence following in the majority of instances within a month
after treatment. There was little or no effect on the sebaceous secretion itself, either in the
formation of oil on the skin or as comedones.
Only one patient was intolerant of the drug, manifesting diarrhea to the extent of having
to discontinue therapy. No untoward effects, such as monilial overgrowth or disturbance
in the bacterial balance, were noted. The drug is apparently safe and is valuable for the
control of the pustular phase of acne vulgaris but has little effect on the basic sebaceous
overactivity.
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